d be used to determine the therapeutic response to GLUMETZA and identify the minimum effective dose. Thereafter, glycosylated hemoglobin should be measured at intervals of approximately three months. The therapeutic goal should be to decrease both fasting plasma glucose and glycosylated hemoglobin levels to normal or near normal by using the lowest effective dose of GLUMETZA, either when used as monotherapy or in combination with sulfonylurea or insulin.
Monitoring of
Manufacturer
Physicians Total Care, Inc.
Active Ingredients
Source
U.S. National Library of Medicine
DailyMed
Last Updated: 2nd of March 2011
